Sorin CE marks self-anchoring aortic heart valve
This article was originally published in Clinica
Sorin (Milan, Italy) has CE marked its Perceval S aortic heart valve for sale in Europe. The self-anchoring biological valve is indicated for the minimally-invasive surgical replacement of the aortic valve in patients with aortic stenosis. Around 3% of 75-year-old patients have severe symptomatic aortic stenosis and if the disorder is untreated, the average survival is only two to three years. The Perceval S is made of bovine pericardium and is mounted on a super-elastic alloy frame.
You may also be interested in...
Dr Noam Emanuel is the founder and chief technology officer of Ness Ziona, Israel-based drug delivery firm PolyPid. The 15-strong firm, established in 2008, has developed an encapsulation technology which allows the precise targeting of drug release.
Mesoblast has received the all-clear from the US FDA to start a Phase III clinical trial for bone marrow regeneration in patients with blood cancers. The study will be conducted together with Mesoblast's strategic alliance partner, Cephalon, which will fund the trial.
Mesoblast has received the green light from the US FDA to begin a Phase II trial of its proprietary adult mesenchymal precursor cell (MPC) product for the treatment of degenerative disc disease, a major cause of chronic low back pain.